论文部分内容阅读
多危险因素干预实验资料研究表明,糖尿病病人冠心病发生的主要危险因素与非糖尿病病人一样是高胆固醇血症、吸烟和舒张压的增高,而糖尿病患者冠心病的患病率为非糖尿病者的两倍,故推测如能降低糖尿病人的胆固醇也能降低糖尿病病人发生冠心病的危险性。Simvastatin 是一类新药物,它竞争性抑制8-羟-3-甲基戊二酰辅酶 A 还原酶。此类药高效降低胆固醇,可降低低密度脂蛋白(LDL)胆固
Multi-risk factors intervention experimental data show that the main risk factors for coronary heart disease in diabetic patients with hypercholesterolemia is the same as non-diabetic patients, smoking and diastolic blood pressure increased, while the prevalence of coronary heart disease in diabetic patients with non-diabetic Twice, it is speculated that if you can reduce the cholesterol of diabetic patients can reduce the risk of coronary heart disease in diabetic patients. Simvastatin is a new class of drugs that competitively inhibit 8-hydroxy-3-methylglutaryl coenzyme A reductase. Such drugs to reduce cholesterol, can reduce low-density lipoprotein (LDL) gall